CD8A and neoplasm: Although the sample size was small, BEMPEG monotherapy was observed to increase the frequency of programmed death 1 (PD-1)-positive CD8+ tumor-infiltrating lymphocytes (TILs) in the TME, supporting its use in combination with NIVO11.